IL6 and rheumatoid arthritis: On the basis of our results, the launch of inhibitors for IL-6 or gp130 as a novel class of anti-inflammatory drugs should not only give rise to great hopes for the treatment of inflammation in rheumatoid arthritis [61-63] but also for alleviation of sustained pain as the symptom that most severely reduces the patients' quality of life.